Life has evolved on this planet with regular daily spans of direct solar energy availability alternating with nocturnal spans of dark. Virtually every earth-borne life form has factored this circadian pattern into its biology to ensure the temporal coordination with its resonating environment, a task essential for its individual survival and that of its species. The first whole genome inspections of mutations in human colon and breast cancer have observed specific retained clock gene mutations. Single nucleotide polymorphisms within the genes of clock, clock-controlled, and melatonin pathways have been found to confer excess cancer risk or protection from cancer. Experimental studies have shown that specific core clock genes (Per2 and Per1) are tumor suppressors because their genetic absence doubles tumor numbers, and decreasing their expression in cancer cells doubles cancer growth rate, whereas their overexpression decreases cancer growth rate and diminishes tumor numbers. Experimental interference with circadian clock function increases cancer growth rate, and clinical circadian disruption is associated with higher cancer incidence, faster cancer progression, and shorter cancer patient survival. Patients with advanced lung cancer suffering greater circadian activity/sleep cycle disruption suffer greater interference with function, greater anxiety and depression, poorer nighttime sleep, greater daytime fatigue, and poorer quality of life than comparable patients who maintain good circadian integration. We must now determine whether strategies known to help synchronize the circadian clocks of normal individuals can do so in advanced cancer patients and whether doing so allows cancer patients to feel better and/or live longer. Several academic laboratories and at least 2 large pharmaceutical firms are screening for small molecules targeting the circadian clock to stabilize its phase and enhance its amplitude and thereby consolidate and coordinate circadian organization, which in turn is likely to help prevent and control human cancer. These drugs and strategies can, in turn, be used to make cancer patients with advanced disease feel and function more normally.
the earth) have been the dynamic local reality. 3 Each organism and every species, prokaryote or eukaryote, that has ever lived has had to deal successfully with regular predictable energy overload and dearth during specific predictably alternating phases of each solar day. Daytime loads of gamma, X, UV, visible, and infrared radiations have had to be effectively dealt with as has the storage of energy through each dark cold night. Protection of the fundamental machinery of life from vast amounts of daytime energy (about 239.4 W/m 2 of the earth's surface) and nighttime energy drain has thereby necessarily been accomplished by the evolution of clocks that anticipate each phase of the geo-solar cycle to protect compartments of the cellular machinery and biochemical and genetic processes most sensitive to solar destruction within the night and temporally segregating less sensitive essential life processes to the energy-filled daytime. 3 A range of protective biochemical processes have also been successfully evolved to protect this essential machinery of life from excess daytime solar, chemical, and biochemical energy and the free radicals they generate. These chemical buffering systems have also been precisely clocked to be most available at times of day when the excess energy burdens from either the sun or essential internal biochemistry is most damaging.
The consequences of mistiming essential radiation or biochemical free radical defenses remain today severe and irreversible and continue to lead to and fine-tune the naturally selected complex resonating time structures most compatible with and supportive of life's flourishing. These essential circadian clocks have evolved, re-evolved, and coevolved numerous times and been retained over the last 2 billion years, attesting to their relevance and importance. [4] [5] [6] The evolutionary roots of this circadian time structure are evident in the clocking and timing of cellular proliferation, apoptosis, and DNA damage repair, among all other fundamental processes within human tissues, and these processes remain temporally organized within cancers derived from those tissues in modern man as well as in all other species. [7] [8] [9] [10] Each of these 3 fundamental processes is central to cancer development progression and its successful therapeutic control. This circadian time structure, if properly understood, provides unique and broad opportunities to prevent, better diagnose, and control human cancer and to diminish human suffering conferred by cancer-associated circadian disruption. 11
Examples of the Circadian Clocking of Normal and Cancerous Cells Skin
Human skin hides its exquisitely radiation-sensitive mitotic machinery from the sun by gating almost all daily cell division within the nighttime hours. This permits safe daytime skin sun exposure to provide essential vitamin D without damaging or killing skin cells not undergoing cell division at that time. Cancers derived from these skin cell precursors also maintain this circadian proliferative gating. 8, 12 This temporal organization of cancer cell division provides the opportunity to increase cancer cell kill by giving antiproliferative agents at the specific times of day when the cancer cell proliferation is most active.
Gut
The epithelial lining of the human gastrointestinal tract, from lips to anus, organizes its continuous renewal through both proliferation and apoptosis within each day. 13 The darkness of the intestinal milieu does not require that proliferation, mitosis, and cell division be limited to the nighttime hours. These processes, in fact, occur most frequently in these tissues during the daytime hours. Food and its local and systemic metabolic effects also stimulate intestinal epithelial cell proliferation. This daytime food effect further helps organize mitosis within the daylight hours of each day 14, 15 within the epithelial lining of the human gut. Consistent with this time structure of normal cell proliferation, colon cancer sensitivity to agents targeting the DNA synthesis phase of the cell cycle are more effective against colon cancer when given during the second half of each night when most DNA cell synthesis occurs in preparation for the usual daytime peaks in cell division 15 in colonic epithelial cells.
Bone Marrow
Human bone marrow hematopoetic cell DNA synthesis, mitosis, and cellular proliferation are each highly organized within each day. 16 The peak times of red and white blood cell precursor proliferation differ, but both are most robustly active during each daytime span and lowest during the middle of each night. 17 Human bone marrow depression is markedly alleviated by providing cytotoxic drugs targeting proliferating bone marrow cells during each night rather than in the daytime hours. 16 This strategy has resulted in increasing the therapeutic index of several categories of common anticancer drugs several fold, simply by optimally timing those agents during the circadian cycle. 18, 19 
Stem Cell Harvest Efficacy
The reality of hematopoietic stem cell circadian clocking is strongly and unequivocally supported by numerous reports of the effect of timing the harvest of human hematopoietic stem cells and progenitor cells with or without G-CSF (granulocyte colony-stimulating factor) stimulation. 20, 21 Other studies demonstrating clear and unequivocally circadian organization of the proportion of each precursor cell type G 1 , S, G 2 , and M phase in the human or mouse bone marrow demonstrate that all aspects of cellular proliferation and maturation within this important target tissue are unequivocally and reproducibly organized within each day. 17, 21 
Hematopoietic Cancers
Several lines of evidence indicate that mouse cancers as well as human cancers derived from bone marrow cells maintain circadian coordination of their cell cycle traverse. This residual circadian organization can be used to advantage by timing cytotoxic drugs when these cancer cells are proliferating most actively (ie, in the daytime). [22] [23] [24] [25] Free Radical Protection Biochemistry Important protectors against DNA damage, including reduced glutathione and all the enzymes and pathways responsible for the production, reduction, and transport of this essential toxicity modulator into the nucleus, prominently peak within human hematopoietic precursor cells at the end of the night, in the very early morning hours (4-6 am) in preparation for the early daytime peak in DNA synthesis and later daytime hematopoietic cell division. Giving oxidatively active cytotoxic anticancer drugs or radiation in the early hours when these free radical defenses are most profound results in much less damage to these essential progenitor cells than if these agents are given later in the daytime hours. 26, 27 
Using Circadian Clocks to Control Cancer
Traditional cytotoxic as well as virtually all newer targeted anticancer therapies exert their anticancer effects by inhibiting and/or accelerating one or more classes of prominent complex cellular processes essential for cell growth and tissue development. Three of the fundamental processes that go awry in precancerous and cancerous cells and tissues include proliferation, apoptosis, and DNA damage repair. These complex processes do not occur randomly during each day either in healthy or cancerous cells. Each is gated by central and cellular circadian clocks, working together to keep these physiological processes coordinated within the rhythmically changing daily environment. The vast majority of cytotoxic and targeted anticancer therapies interfere with one or more aspects of cellular proliferation, such as DNA synthesis or mitosis, at specific cell cycle check points, the traverse of which are organized in circadian time, each day. 8, 15 Other therapeutic target elements include those essential for the proper kinesis of mitosis, whereas still others modulate the ability of DNA to be repaired after it is damaged by cytotoxic drugs, irradiation, or targeted agents that specifically interfere with the molecular components essential for DNA repair. 9, 28, 29 The lethality induced by many general and specific insults to cellular proliferation, DNA damage repair, and cellular metabolism operate through the final common pathways of apoptosis, and/or autophagy and/or necrosis. There is growing molecular, preclinical, pathological, and clinical evidence that each of these fundamental processes essential for the control of cell death and removal and/or survival, growth, and division is tightly controlled by the cellular circadian clock. 30 If this is so, then any agent successfully targeting and modulating any of these fundamental processes in either normal or malignant cells and tissues will do so more or less effectively, depending on whether it is made available at a time of day when this process is either highly active or latent.
Cancer Prevention
Because all human tissues organize their critical functions to specific times of day, one might imagine that there might be biological and health consequences to disturbances of this circadian temporal organization. Increasing cancer risk is one of these consequences. Preclinical and clinical data indicate that chronic disruption of the circadian cycle leads to an increased risk for cancer and that acute disruption of daily rhythms can immediately increase cancer proliferation and growth rate. 15 These facts give additional reason to think that the circadian clock controls of cellular proliferation, apoptosis, and DNA damage repair must be maintained intact to prevent cancer.
Experimental Systems
Mice harboring solid tumors who experience acute clock disruption, accomplished by continuous experimental jetlag, have more rapidly growing tumors than identical syngeneic mice with the same tumors, living under regular circadian conditions. 31 The tumors of mice exposed to even small amounts of light during nighttime hours grow measurably faster than those shielded from light at night. 32 Tumors in mice in which the central circadian clock within the hypothalamus (bilateral suprachiasmatic nuclei) has been physically destroyed grow faster than in mice with sham operations and intact suprachiasmatic nuclei. 33 Finally, tumors growing in mice exposed to constant moderately bright light at night immediately accelerate their tumor cell proliferation and double their growth rates when the lights are kept on during each night. 34 
Genetic Clock Disruption
At least 2 of the 9 core circadian clock genes, Per1 and Per2, have tumor suppressor activity. [35] [36] [37] When these genes are knocked out, mutated, or knocked down in cancer cells, cancers comprised of such cells grow twice as fast as genetically intact otherwise identical tumor cells, both in vitro and in vivo. These cancer cell proliferation and tumor growth effects of clock gene downregulation operate through b-catenin-related pathways and occur in both mouse and human cancer systems. 36 
Clinical, Genetic, and Environmental Evidence of the Importance of Clock Genes to Cancer Control
A growing clinical evidence base that is largely epidemiological but also contains some growing biological genetic evidence indicates that an intact circadian clock and a regular circadian schedule, each protect human beings from common epithelial and some hematological cancers. 38 
Breast Cancer
Women participating in rotating and/or night shift work, which necessarily exposes them to light at night, disturbs their circadian time structure and increases their risk of breast cancer by some 50%. 39, 40 Both the pineal and melatonin as well as clock genes are, apparently, relevant to this increased breast cancer risk. Overnight melatonin urinary excretion is diminished by light at night and by its attendant circadian disruption. 41 Women working at night who have the lowest overnight urinary melatonin excretion, an excellent measure of the degree of circadian disruption, have the highest breast cancer risk compared with women working in the day and with women working in the night with higher levels of overnight melatonin excretion. 42 Additional work indicates an inverse relationship of melatonin (protective) and estrogen with breast cancer risk. 43 This is relevant because estrogen exposure, both endogenous and exogenous, is among the strongest of breast cancer risk factors.
Colon Cancer
Women and men chronically exposed to night and rotating night shift work have a 50% increased risk of developing colon cancer compared with controls working only during days. 41 Several mouse models demonstrate tumor suppressor effects of Per1 and Per2 clock genes on colon cancer proliferation. This is also the case for human colon cancer cells. [44] [45] [46] Colon cancer is among the most common and commonly lethal human cancers in the developed world.
Core Circadian Clock Gene Mutations and Single Nucleotide Polymorphisms (SNPs) in the Clock Genes of Human Cancers
Nonsynonymous (Per1 and/or Per2) clock gene mutations have been discovered to have been retained in some human colon and breast cancers. 47, 48 More subtle single SNPs have also been discovered, which modulate the risk of human colon and breast cancer, indicating that normal clock gene function is essential, at least in part, to protect optimally against the development of these most common epithelial cancers. 49, 50 Other Human Cancers Shift work has also been associated with statistically significant increased incidences of prostate cancer, endometrial epithelial cancers, and certain lymphomas and leukemias. Clock gene SNPs have also been shown to modulate both the risk for and biological behavior of these human cancers. [51] [52] [53] To Sum Up These pieces of epidemiological, biological, molecular, and genetic information taken together make it likely that the normal clock gene gating of fundamental cellular processes is essential to prevent cancer or diminish the propensity toward cancer development. They also support the likelihood that after cancer is initiated, its aggressiveness depends, to some extent, on the presence of these normal circadian controls. Cancers losing these controls grow faster and kill sooner than those in whom more of these normal physiological circadian controls are maintained intact. Thereby, in principle, the timing of virtually any agent that targets one of more of these essential processes will either enhance or diminish anticancer efficacy depending on when in the 24-hour day it is applied. 11 Because the clock itself normally controls and gates each of these and most, if not all, critical cell processes, then necessarily, modulating the clock itself or the clockcontrolled gene products that link these fundamental cellular processes to the clock will have the potential to induce that control over cancer cell proliferation, apoptosis, and/or DNA damage repair. Given the ubiquity of circadian clock control of these processes, it is entirely reasonable to hypothesize, if not to expect, that blocking or enhancing certain specific clock-controlled pathways will control cancer growth. This strategy would uncover an entirely novel and potentially robust group of cancer control targets and block targeted molecular agents to modulate them.
Cancer as a Cause of Symptomatic Circadian Disruption
Every cell in our body has oscillators involved in the sending and receiving of signals that regulate the physiological economy of the body. Many of these oscillators have a circadian period, and their synchronization integrates the many physiological and behavioral processes required to meet the challenges of daily life. 54 The experimental destruction of an animal's rest activity rhythms accelerates tumor growth, whereas restoring normal circadian function enhances the survival benefits of chemotherapy. 55 However, there have been surprisingly few studies that have collected data on the circadian function of cancer patients. What little is known confirms the preclinical data that link distorted circadian function with accelerated tumor progression. Hrushesky 18 first documented abnormal circadian patterns among cancer patients. Mormont et al 56 found that a flattened rest-activity circadian rhythm in metastatic colon cancer patients was an independent predictor for treatment failure and premature death. Similarly, an abnormally flat circadian cortisol rhythm in metastatic breast cancer patients was an independent predictor of survival. 57 Although direct measurements of circadian function in cancer patients are sparse, data on behaviors or symptoms linked to disrupted circadian function, such as sleep quality and fatigue are more common. For example, the subjective sleep quality of cancer patients approaches levels found in insomniacs. [58] [59] [60] Consequently, disturbances in sleep patterns may account for some of the symptoms that plague cancer patients-daytime fatigue and emotional problems such as irritability, depression, and decreased pleasure in work and social activities. 61, 77 Fatigue is linked to disrupted sleep rhythms, and the prevalence of fatigue rises to more than 80% in patients undergoing chemotherapy. 35 Indeed, approximately 50% to 75% of cancer patients have fatigue levels that impair healthrelated quality of life (QoL) at diagnosis. Consequently, it is not surprising that cancer treatment-related fatigue is not necessarily ameliorated by aerobic exercise.
Careful observation of the natural history of neoplastic diseases reveals a link between disrupted circadian and sleep functions and many of the symptoms that degrade the patients' QoL. It is uncertain how cancer treatment affects circadian function. 35 There is emerging evidence that suggests that cancer patients are at high risk for problems associated with disrupted circadian function: poor sleep quality, fatigue, and decreased QoL.
Lung cancer is the most commonly lethal cancer worldwide. The introduction of platinum compounds into the treatment of advanced non-small-cell lung cancer (NSCLC) significantly enhanced survival of patients who are either refractory to or relapse following first-line chemotherapy. 62 None of these protocols, however, have exploited the circadian rhythms that regulate the timing of gene activity and cell function. Today, investigators have discovered that the rest-activity cycle is a reliable marker of the circadian system. 54 There is accumulating preclinical and clinical evidence that patients with advanced cancer placed on chronotherapeutic protocols have a significantly longer life span and higher QoL scores and experience fewer and less intense symptoms. 56 The chronobiotic clock-resetting agent and sleepfacilitating hormone melatonin plays a significant role in the synchronization of the sleep-wake cycle. Distortions in the production or release of melatonin have been linked to a variety of symptoms such as insomnia and daytime drowsiness. 63 Others have shown that diminished circadian amplitudes and dampened nighttime melatonin release characterize the melatonin circadian dynamics of patients with cancer. [64] [65] [66] Lewy et al 67 have repeatedly demonstrated the capacity of orally administered melatonin to reset the circadian clock. 67 The medical literature reports that melatonin produces a variety of favorable outcomes in oncology patients. Lissoni's group reports that melatonin reduces the toxicity of various chemotherapeutic agents, including cisplatin, etoposide, anthracyclines, and 5-fluorouracil. They found a statistically significant reduction in treatment-related adverse events, such as myelosuppression, neurotoxicity, nephrotoxicity, cardiotoxicity, and asthenia. [68] [69] [70] [71] We have designed a multicenter trial to evaluate the chronotherapeutic role of melatonin in the treatment of patients with stage III and IV NSCLC and to analyze the relationships between circadian function, fatigue, insomnia, and overall QoL. Here, we report the circadian function, sleep quality, and levels of fatigue prior to treatment in a group of patients with advanced NSCLC. Table 1 summarizes the actigraphy data during putative daily wake spans and compares 33 cancer patients with a reference population of 35 normal adults. 72 These control data were obtained from a heterogeneous group of 35 adults who were 20 to 50 years old, who wore actigraphs for 3 days on the average, and had no known disease or chronic condition. We found that in all parameters, cancer patients were significantly different from the reference population. Table 2 depicts actigraphy data during putative daily sleep spans. As during the wake span, the cancer patients differed from the reference population in all parameters. In both wake and sleep cycles and for all parameters, actigraphy data of cancer patients indicate fractured and disrupted circadian function.
Sleep and Activity Patterns of Lung Cancer Patients Compared With Controls Actigraphy Data

Differences in Actigraphy Baseline Data by Site
There were significant differences in actigraphy results by site. Actigraphy data were recorded and obtained in the inpatient setting at the Midwestern Regional Medical Center (MRMC) and in the patients' homes for Veterans Affairs Medical Center (VAMC) patients. Consequently, a simultaneous comparison of circadian parameters (Bingham test) found that the average circadian rhythms of patients at both sites were significantly different (F = 16.86; P < .01). For example, VAMC patients had higher circadian amplitudes, indicating more robust rhythms (F = 4.46; P = .04). WJB Dorn VAMC patients were more active as indicated by their higher peak activity (F = 4.84; P = .036). Also, the daynight activity difference was greater in VAMC patients as indicated by the higher I<O (ie, movement in bed versus out of bed; 90.0 ± 2.2 vs 78.9 ± 2.4). They also had a more stable circadian rhythm pattern as exhibited by the higher mean 24-hour autocorrelations (F = 5.41; P = .029).
Sleep
Pittsburgh Sleep Quality Index (PSQI) data showed that the lung cancer patients scored consistently higher than a control group in all 7 component scores. Consequently, the mean Global Sleep Quality Score for the study population is 10.6, which is more than 2.0 points from the 4.8 score and much higher than the score of 5 that identifies poor sleep quality in cancer-free individuals ( Table 3) . 73 Although there was no statistically significant difference by site for the global sleep quality, there were statistically significant differences in 2 of the 7 components of the PSQI. Sleep quality was statistically significantly better among veteran patients at the VAMC (1.5 ± 0.20) than among MRMC patients (2.3 ± 0.3; F = 5.60; P = .025). Moreover, MRMC patients used more sleep medications than VAMC patients (F = 5.88; P = .022).
Quality of Life
Patients with advanced NSCLC reported lower scores for all European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C3) domains when compared with population-based controls (Table 4 ) despite the differences in the sites by patients' age and clinical scores. Nonetheless, VAMC patients showed a statistically significant lower physical function of 47.3 compared with MRMC's 69.5 (P < .001), which may reflect the fact that VMAC patients were older. In addition, there was a 22-point difference in the dyspnea item-38.1 for MRMC compared with 60.6 for VAMC patients (P < .014). This indicates that VAMC patients experienced worse dyspnea condition as compared with MRMC patients. Table 5 reports the results from the Ferrans and Powers quality of life index (QLI) and compares the mean scores of the study population with population-based data provided by Ferrans. The MRMC patients' score of 12.5 was statistically significantly lower than the VAMC patients' score of 18.7 (P < .04). Interestingly, MRMC patients' capability of completing the physical activities of daily life was statistically significantly higher in the EORTC physical domain, but their dissatisfaction with their capacity to fulfill the activities of daily living was much higher than that of the VAMC patients.
Circadian Function and QoL Outcomes by Performance Status
In NSCLC, patients with a Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 2 have a much poorer prognosis and experience lower rates of tumor response to therapy than patients with PS of 0 and 1. 74 Several circadian sleep/wake parameters were computed to assess and compare the sleep characteristics of patients with different performance statuses. The mean duration of long sleep episodes fell from 129 minutes for patients with a PS of 0 to 96.5 minutes in PS 2 patients (P < .05). This indicates that patients with poor performance status (PS 2) tend to have more disturbed sleep during the night. These long sleep spans, however, are short compared to those of normal adults, which average 225 minutes. Similarly, the mean duration of activity during wakefulness was unaffected by the PS score; however, patients with PS 2 tended to be less active than patients with PS 1. In the normal population, the duration of mean activity during wakefulness was 182.6 minutes, which is nearly 60 minutes longer than our PS 0 patients. Although the number of sleep interruptions nightly was not statistically significant among PS levels, there were more sleep interruptions in patients with poor PS compared with those with good PS (Table 6 ). We evaluated several cosinor parameters such as circadian amplitude, circadian fragmentation/amplitude of ultradian rhythms, circadian quotient, peak activity, activity/rest dichotomy (I<O), and rhythm quotient to measure the relationship between circadian function and PS. The only circadian function that was statistically significantly different in this small sample was the frequency of ultradian 4-hour rhythms (P < .046). Higher 4-hour amplitudes indicate disruption of the circadian rhythm, which normally has 1 peak. The circadian quotient, which provides a measure of the strength of the circadian rhythm compared with other components, suggests that circadian rhythms are more pronounced in patients with PS 0 or 1 than in patients with PS 2. The daily activity of normal people usually has 1 or 2 circadian peaks, with best cosine fit at 24 or 12 or 12 and 24 hours. The rhythm quotient provides a basis for assessment of the degree of activity/sleep consolidation within each day. A higher circadian rhythm quotient indicates a more pronounced circadian rhythm, and lower values indicate fractured circadian sleep-activity patterns. From Table 6 , it is known that the rhythm quotient has an inverse relationship to PS levels. This indicates that patients with scores of 0 or 1 have less fractured circadian sleep-activity patterns. Furthermore, 24-hour autocorrelations (r24) are higher in patients with PS 0, although not 
Discussion
Advanced Lung Cancer Causes Symptomatic Circadian Disruption
NSCLC patients were recruited on a clinical trial that investigates whether exogenous melatonin at the appropriate circadian time improves health-related QoL, diminishes patient fatigue, and enhances sleep quality and quantity by a statistically significant level. We report our analysis of the baseline status of the initial 33 trial participants to determine whether patients with advanced NSCLC have distorted circadian rhythms, poor sleep quality, and compromised QoL. We did this analysis because there are few data in the clinical literature on the circadian function of cancer patients, in general, and NSCLC patients, in particular. 56, 75 Moreover, the literature has even fewer data on the relationships between circadian function, PS, and QoL.
Our analysis found that patients with advanced NSCLC have distorted circadian rhythms. Trial participants experienced higher than expected levels of wakefulness during the normal sleep period and surprisingly extensive sleep periods during normal times for activity. The patients, for example, spent 71.2% of the putative sleep time "sleeping," whereas a "normal person" spends 93% of the putative sleep time "sleeping." Conversely, these good PS cancer patients were sleeping 21.8% during the putative wakefulness time, whereas normal people spend only 4.7% of the day completely inactive. All other actigraphy data items confirm this pattern of excess rest during the activity phase of the circadian cycle and increased activity during the rest phase of the daily cycle of sleep and activity. Cosinor analysis shows clearly that our patients' circadian rhythm functions are significantly different from that of normal persons. However, because of the obvious age and gender differences between our patient cohorts and the reference population, we need age-and gender-matched comparisons to adequately evaluate the circadian patterns of our patient population.
Curiously, there was no correlation between a patient's PS score and any actigraphy data item. PS is the most useful stratification variable for predicting patient response and survival. 76 For example, the potential life span of a PS 2 patient is considerably shorter than that of a patient with a PS of 1. The actigraphy data indicated that the occurrence of a stage III or IV cancer, pretreated or newly diagnosed, produces severe significant impairment in the patient's circadian function. A circadian rhythm has a 24-hour period. Cosinor analysis revealed that circadian rhythms of patients with a PS of 2 were more distorted than those of patients with a PS of 0 or 1. Consequently, patients with more advanced disease experience a greater disruption in their circadian rest/activity cycle.
Sleep Is Greatly Disturbed
As expected, sleep quality data from the PSQI confirm the actigraphy data. Patients' PSQI Global Sleep Quality Score of 10.6 is well above the threshold level of 5 for poor sleep quality. With the exception of daytime dysfunction, the sleep instrument found no statistical differences by performance status scores. Consequently, both the actigraphy and PSQI reveal that patients with advanced NSCLC, irrespective of their treatment history, have very poor sleep quality. More important, the very poor sleep quality of these patients was independent of the patients' PS score. This means that by the time advanced lung cancer patients present for therapy, their circadian organization has been greatly disturbed.
Clinical research among noncancer patients has linked poor sleep quality with lower scores in instruments measuring health-related QoL. The self-report of QoL scores among participants in this trial were significantly lower than those of the general population. The mean scores for the EORTC functional domains, with the exception of the cognitive domain, were more than 20 points less than those reported in population-based surveys. Moreover, in the EORTC symptom items, our trial participants reported a greater than 20-point increase (worse symptoms) in a variety of EORTC symptom items (pain, fatigue, dyspnea, insomnia). These data make it clear that the trial participants' ability to fulfill the activities of daily life is much lower than that of the general population.
Circadian Disruption Diminishes Functional Status and Quality of Life
The EORTC instrument emphasizes the patients' capacity to perform the activities of daily living, but the QLI evaluates the patients' degree of satisfaction with their QoL. The trial participants' health and function domain score is at the bottom quintile of the general population. Thus, our patients are expressing a high degree of dissatisfaction with their capacity to fulfill the activities of daily life. Interestingly, despite the difficulties the trial patients were experiencing in meeting the challenges of daily living, they still expressed satisfaction with key aspects of life-social and economic, psychological and spiritual, and family-that is similar to that of the general population.
Unlike the actigraphy and PSQI data, the PS scores stratified the QoL results. The EORTC functional domain scores were highest in patients with a PS 0 status and lowest in PS 2 patients. Moreover, the symptom items tended to increase with increasing PS scores, and the fatigue scores for PS 2 patients were twice the scores reported by PS 0 patients. The QLI instrument separated patients with PS 0 but did not differentiate PS 1 and 2 patients.
Significant differences between the 2 study sites were observed in almost all the circadian parameters. We attribute this to the different milieux when actigraphy is measured. Actigraphy was obtained in VAMC patients in the ambulatory/home setting prior to therapy and in hospital during chemotherapy in MRMC patients. As a result, the MRMC patients might have been more sedentary than usual. Circadian rhythms of patients in MRMC were less robust, and day-night activity differences were less pronounced. Furthermore, the day-to-day rhythm of VAMC patients is more stable compared with MRMC patients, indicated by the 24-hour autocorrelation. Patients with advanced NSCLC have distorted circadian function independent of their PS. Indeed, the development of an advanced NSCLC is accompanied by very unsubtle distortions in an individual's circadian function. Moreover, the patients exhibit each of the expected symptoms of individuals suffering from disrupted circadian function: complaints of poor sleep quality, fatigue, and insomnia. We also documented the superiority of outpatient/home as opposed to inpatient actigraphy for most accurately measuring and assessing the circadian organization of cancer patients.
To sum up, we conclude that the daily sleep-activity patterns of patients with advanced lung cancer are disturbed. These are accompanied by marked disruption of QoL and function. These data argue for investigating how much of this poor functioning and QoL are actually caused by this circadian disruption and whether behavioral, light-based, and/or pharmacological strategies to correct the circadian sleep-activity patterns can improve function and QoL.
Disturbance of circadian organization increases cancer risk, increases cancer progression rate, diminishes QoL and life function and shortens cancer patient survival. Developing strategies to effectively prevent circadian disruption in patients without cancer, to prevent it, and effective strategies to diminish circadian disruption among patients with cancer are each worthwhile and accomplishable goals.
